{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:23:50Z","timestamp":1781731430948,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heparin\u2010induced thrombocytopenia (HIT) is a potentially serious adverse drug reaction that can result in lethal vascular thrombosis. Dabigatran is a direct thrombin inhibitor that might be useful in the management of HIT. This study evaluated the efficacy and safety of dabigatran in patients with HIT. We included 43 patients in the study who received dabigatran for the management of suspected HIT, based on 4Ts (thrombocytopenia, timing of platelet count drop, thrombosis or other sequelae, and other causes of thrombocytopenia) scores. Three patients were excluded because they had received dabigatran with a creatinine clearance &lt;15\u00a0mL\/min. Patients\u2019 records were analyzed longitudinally, with 12\u00a0months follow\u2010up from the time of initiation of dabigatran, for occurrence of thrombosis, dabigatran\u2010related complications, and outcome. Patients with chronic kidney disease, hepatic impairment, mechanical heart valves, active bleeding, and extremes of weights (&lt;50 and &gt;120\u00a0kg) were excluded from the study. Arterial thrombosis was not observed in any of our patients. The platelet counts normalized in all patients except for 2, which was attributed to the underlying comorbidities. We did not observe any hemorrhagic events or significant thrombosis during the follow\u2010up period. Eight patients died from nonthrombotic causes, which were unrelated to adverse effects of dabigatran. Based on our findings, dabigatran could be considered a safe and effective agent in the management of HIT, particularly in the developing countries, where there could be issues with the cost and availability of other agents recommended for this condition. Further studies are needed to validate our findings.<\/jats:p>","DOI":"10.1002\/jcph.1300","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T21:42:20Z","timestamp":1538775740000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dabigatran as a Treatment Option for Heparin\u2010Induced Thrombocytopenia"],"prefix":"10.1002","volume":"59","author":[{"given":"Somayyeh","family":"Nasiripour","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy\u2010International Campus Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Saif","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Firoozgar Clinical Research Development Center Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farasatinasab","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Firoozgar Clinical Research Development Center, School of Pharmacy\u2010International Campus Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepide","family":"Emami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Firoozgar Hospital Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Amouzegar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Firoozgar Clinical Research Development Center Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Basi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Firoozgar Clinical Research Development Center Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Department of Medicine Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322003"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00258-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-12-0825"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13330"},{"key":"e_1_2_9_6_1","first-page":"43","volume-title":"Heparin\u2010Induced Thrombocytopenia","author":"Warkentin T","year":"2000"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01787.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015579424"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.12.007"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353391"},{"issue":"1","key":"e_1_2_9_12_1","first-page":"155","article-title":"In\u2010vitro profile and ex\u2010vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen W","year":"2007","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1137-66272012000300024"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.01.009"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.06.013"},{"issue":"1","key":"e_1_2_9_16_1","first-page":"112","article-title":"Dabigatran, a direct thrombin inhibitor, can be a life\u2010saving treatment in heparin induced thrombocytopenia","volume":"9","author":"Mirdamadi A","year":"2013","journal-title":"ARYA Atheroscler"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-07-0593"},{"key":"e_1_2_9_18_1","first-page":"985253","article-title":"Heparin\u2010induced thrombocytopenia in a patient with essential thrombocythemia: a case\u2010based update","volume":"2015","author":"Noel E","year":"2015","journal-title":"Case Rep Hematol"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2015.95"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778993"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.14.1838"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1300","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T19:58:11Z","timestamp":1694807891000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1002\/jcph.1300"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1300","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"2018-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}